| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Urinary Catheters | 3 | 2018 | 35 | 1.54 | Why? |
| Singapore | 35 | 2021 | 3641 | 1.50 | Why? |
| Urinary Tract Infections | 7 | 2018 | 534 | 1.39 | Why? |
| Catheter-Related Infections | 4 | 2018 | 381 | 1.24 | Why? |
| Escherichia coli Infections | 5 | 2018 | 348 | 1.09 | Why? |
| Mycoses | 2 | 2018 | 589 | 0.90 | Why? |
| Catheters, Indwelling | 2 | 2018 | 84 | 0.85 | Why? |
| Directly Observed Therapy | 1 | 2019 | 34 | 0.81 | Why? |
| Talipes Cavus | 1 | 2018 | 1 | 0.77 | Why? |
| Biofilms | 3 | 2018 | 304 | 0.75 | Why? |
| Streptococcal Infections | 2 | 2019 | 255 | 0.74 | Why? |
| Drug Resistance, Multiple, Fungal | 1 | 2018 | 45 | 0.72 | Why? |
| Microscopy, Electron, Scanning | 1 | 2018 | 221 | 0.67 | Why? |
| Expert Systems | 1 | 2017 | 42 | 0.67 | Why? |
| Oral Surgical Procedures | 1 | 2017 | 60 | 0.65 | Why? |
| Enterovirus A, Human | 1 | 2019 | 180 | 0.65 | Why? |
| Foot | 1 | 2018 | 195 | 0.65 | Why? |
| Patient Portals | 1 | 2017 | 84 | 0.64 | Why? |
| Bacteremia | 4 | 2019 | 1372 | 0.62 | Why? |
| Silver | 1 | 2018 | 327 | 0.58 | Why? |
| Tuberculosis, Pulmonary | 3 | 2020 | 1171 | 0.57 | Why? |
| Fungi | 1 | 2018 | 471 | 0.56 | Why? |
| Antibiotic Prophylaxis | 1 | 2017 | 399 | 0.56 | Why? |
| Enterovirus Infections | 1 | 2019 | 404 | 0.55 | Why? |
| Dengue | 4 | 2020 | 1565 | 0.55 | Why? |
| Poverty Areas | 1 | 2019 | 556 | 0.54 | Why? |
| Drug Resistance, Microbial | 1 | 2018 | 419 | 0.53 | Why? |
| Urinary Catheterization | 3 | 2018 | 47 | 0.53 | Why? |
| Pericarditis | 1 | 2019 | 417 | 0.53 | Why? |
| Incidental Findings | 1 | 2018 | 487 | 0.52 | Why? |
| Science | 1 | 2020 | 463 | 0.50 | Why? |
| Influenza A Virus, H1N1 Subtype | 5 | 2019 | 2984 | 0.49 | Why? |
| Endocarditis, Bacterial | 1 | 2017 | 344 | 0.48 | Why? |
| Vaccines, Inactivated | 2 | 2019 | 1562 | 0.48 | Why? |
| Respiratory Protective Devices | 2 | 2014 | 1637 | 0.47 | Why? |
| Radiography | 2 | 2018 | 1576 | 0.44 | Why? |
| Acquired Immunodeficiency Syndrome | 1 | 2017 | 533 | 0.44 | Why? |
| Communicable Diseases, Emerging | 3 | 2019 | 2523 | 0.41 | Why? |
| Cross Infection | 4 | 2020 | 8675 | 0.35 | Why? |
| Oseltamivir | 1 | 2012 | 583 | 0.35 | Why? |
| Immunosenescence | 2 | 2020 | 169 | 0.34 | Why? |
| Cross Protection | 2 | 2019 | 373 | 0.32 | Why? |
| Zoonoses | 2 | 2017 | 3034 | 0.30 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.29 | Why? |
| Drug Resistance, Viral | 1 | 2012 | 1083 | 0.29 | Why? |
| Electronic Health Records | 2 | 2021 | 3492 | 0.28 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.28 | Why? |
| Immunogenicity, Vaccine | 2 | 2019 | 4624 | 0.28 | Why? |
| Coronavirus Infections | 20 | 2020 | 253789 | 0.27 | Why? |
| Coinfection | 3 | 2020 | 6820 | 0.27 | Why? |
| Influenza, Human | 5 | 2019 | 10779 | 0.26 | Why? |
| Escherichia coli | 4 | 2018 | 1547 | 0.25 | Why? |
| Humans | 79 | 2021 | 930598 | 0.24 | Why? |
| Severe Acute Respiratory Syndrome | 5 | 2020 | 12361 | 0.24 | Why? |
| Masks | 2 | 2014 | 8528 | 0.23 | Why? |
| DNA, Catalytic | 1 | 2021 | 48 | 0.22 | Why? |
| Universities | 1 | 2017 | 4374 | 0.22 | Why? |
| Lymphocyte Activation | 2 | 2021 | 2742 | 0.22 | Why? |
| Global Health | 3 | 2020 | 13911 | 0.21 | Why? |
| Immunoglobulin Class Switching | 1 | 2021 | 133 | 0.21 | Why? |
| Female | 40 | 2021 | 380317 | 0.21 | Why? |
| Travel | 5 | 2020 | 7220 | 0.21 | Why? |
| Anti-Bacterial Agents | 7 | 2019 | 10083 | 0.21 | Why? |
| Penicillin G | 1 | 2019 | 14 | 0.21 | Why? |
| Pregnancy Complications, Infectious | 3 | 2021 | 11559 | 0.21 | Why? |
| Zika Virus Infection | 3 | 2019 | 1920 | 0.21 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.20 | Why? |
| Allied Health Personnel | 1 | 2004 | 416 | 0.20 | Why? |
| Volvariella | 1 | 2018 | 1 | 0.19 | Why? |
| Swine, Miniature | 1 | 2018 | 33 | 0.19 | Why? |
| Biomedical Research | 1 | 2020 | 5270 | 0.19 | Why? |
| Swine | 2 | 2018 | 3352 | 0.19 | Why? |
| Pneumonia, Viral | 18 | 2021 | 243684 | 0.19 | Why? |
| Bacteriuria | 1 | 2018 | 31 | 0.19 | Why? |
| Middle East | 2 | 2014 | 1418 | 0.19 | Why? |
| Microfluidic Analytical Techniques | 1 | 2021 | 254 | 0.19 | Why? |
| Betacoronavirus | 13 | 2020 | 204454 | 0.18 | Why? |
| Penicillanic Acid | 1 | 2018 | 58 | 0.18 | Why? |
| Thienamycins | 1 | 2018 | 72 | 0.18 | Why? |
| Mycobacterium | 1 | 2020 | 143 | 0.18 | Why? |
| Streptococcus agalactiae | 1 | 2019 | 194 | 0.18 | Why? |
| Neural Stem Cells | 1 | 2019 | 135 | 0.18 | Why? |
| Urban Health Services | 1 | 2019 | 125 | 0.18 | Why? |
| False Positive Reactions | 2 | 2021 | 1338 | 0.18 | Why? |
| Immunocompetence | 1 | 2019 | 280 | 0.18 | Why? |
| Streptococcus suis | 1 | 2017 | 8 | 0.18 | Why? |
| Povidone-Iodine | 1 | 2021 | 213 | 0.17 | Why? |
| Polyesters | 1 | 2018 | 94 | 0.17 | Why? |
| Viral Vaccines | 1 | 2019 | 7560 | 0.17 | Why? |
| Data Anonymization | 1 | 2017 | 32 | 0.17 | Why? |
| Nervous System Malformations | 1 | 2017 | 43 | 0.17 | Why? |
| Constipation | 1 | 2018 | 99 | 0.17 | Why? |
| Urinary Bladder | 1 | 2018 | 170 | 0.17 | Why? |
| Lab-On-A-Chip Devices | 1 | 2021 | 411 | 0.17 | Why? |
| Ciprofloxacin | 1 | 2018 | 130 | 0.16 | Why? |
| Pneumonia | 1 | 2017 | 5652 | 0.16 | Why? |
| Respiratory Tract Infections | 2 | 2019 | 6817 | 0.16 | Why? |
| Public Health | 3 | 2020 | 16359 | 0.16 | Why? |
| Antimicrobial Cationic Peptides | 1 | 2018 | 159 | 0.16 | Why? |
| Philippines | 1 | 2019 | 568 | 0.16 | Why? |
| Industry | 1 | 2020 | 347 | 0.16 | Why? |
| Fluoroquinolones | 1 | 2018 | 235 | 0.16 | Why? |
| Male | 37 | 2021 | 367725 | 0.16 | Why? |
| Antibody-Dependent Enhancement | 1 | 2020 | 413 | 0.16 | Why? |
| Adult | 28 | 2021 | 244371 | 0.16 | Why? |
| Delayed-Action Preparations | 1 | 2018 | 291 | 0.15 | Why? |
| Oral Hygiene | 1 | 2017 | 137 | 0.15 | Why? |
| Antitubercular Agents | 2 | 2020 | 775 | 0.15 | Why? |
| Proof of Concept Study | 1 | 2018 | 696 | 0.15 | Why? |
| Cephalosporins | 1 | 2018 | 250 | 0.15 | Why? |
| Platelet Transfusion | 1 | 2017 | 209 | 0.15 | Why? |
| Communicable Disease Control | 4 | 2017 | 29620 | 0.15 | Why? |
| Infusions, Intravenous | 1 | 2019 | 1224 | 0.14 | Why? |
| T-Lymphocytes | 3 | 2021 | 6670 | 0.14 | Why? |
| Disease Outbreaks | 6 | 2021 | 27595 | 0.14 | Why? |
| Fear | 2 | 2020 | 3607 | 0.14 | Why? |
| Silicones | 1 | 2013 | 26 | 0.14 | Why? |
| Invasive Fungal Infections | 1 | 2018 | 274 | 0.14 | Why? |
| Aspartate Aminotransferases | 1 | 2021 | 1394 | 0.14 | Why? |
| Environmental Health | 1 | 2017 | 203 | 0.14 | Why? |
| DNA Methylation | 1 | 2019 | 688 | 0.13 | Why? |
| Anti-Infective Agents | 2 | 2018 | 1766 | 0.13 | Why? |
| Influenza A Virus, H3N2 Subtype | 1 | 2018 | 572 | 0.13 | Why? |
| Nanostructures | 1 | 2021 | 700 | 0.13 | Why? |
| Polymers | 1 | 2018 | 507 | 0.13 | Why? |
| Middle Aged | 26 | 2021 | 270681 | 0.13 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2019 | 398 | 0.13 | Why? |
| Dengue Virus | 2 | 2018 | 910 | 0.13 | Why? |
| Asymptomatic Infections | 3 | 2021 | 7218 | 0.13 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.13 | Why? |
| Klebsiella Infections | 1 | 2018 | 466 | 0.13 | Why? |
| Pharynx | 1 | 2021 | 1544 | 0.13 | Why? |
| Healthy Volunteers | 1 | 2019 | 1444 | 0.13 | Why? |
| L-Lactate Dehydrogenase | 1 | 2021 | 1995 | 0.12 | Why? |
| Cell Differentiation | 1 | 2019 | 1338 | 0.12 | Why? |
| Family Characteristics | 2 | 2021 | 2551 | 0.12 | Why? |
| Phylogeography | 1 | 2017 | 824 | 0.12 | Why? |
| Klebsiella pneumoniae | 1 | 2018 | 658 | 0.12 | Why? |
| Influenza B virus | 1 | 2018 | 815 | 0.12 | Why? |
| Drug Administration Schedule | 1 | 2019 | 2324 | 0.12 | Why? |
| Influenza Vaccines | 2 | 2019 | 2941 | 0.12 | Why? |
| Interprofessional Relations | 1 | 2020 | 1013 | 0.12 | Why? |
| Drug Carriers | 1 | 2018 | 590 | 0.12 | Why? |
| Sodium Chloride | 1 | 2013 | 203 | 0.11 | Why? |
| Cause of Death | 3 | 2020 | 4823 | 0.11 | Why? |
| Transients and Migrants | 2 | 2021 | 1468 | 0.11 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.11 | Why? |
| Hospitals, University | 2 | 2020 | 4173 | 0.11 | Why? |
| Infectious Disease Medicine | 1 | 2014 | 311 | 0.11 | Why? |
| Nucleocapsid Proteins | 2 | 2020 | 3120 | 0.11 | Why? |
| Cardiovascular Diseases | 3 | 2021 | 11497 | 0.11 | Why? |
| Metal Nanoparticles | 1 | 2018 | 771 | 0.11 | Why? |
| Molecular Epidemiology | 1 | 2017 | 1638 | 0.11 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 711 | 0.11 | Why? |
| Cytokines | 3 | 2021 | 15010 | 0.10 | Why? |
| Antibodies, Viral | 8 | 2021 | 51949 | 0.10 | Why? |
| Protein Engineering | 1 | 2013 | 536 | 0.10 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.10 | Why? |
| Organizational Innovation | 1 | 2020 | 2468 | 0.10 | Why? |
| Fever | 3 | 2018 | 7795 | 0.10 | Why? |
| Indoles | 1 | 2018 | 1243 | 0.10 | Why? |
| Medication Adherence | 1 | 2019 | 1270 | 0.10 | Why? |
| Endothelium, Vascular | 1 | 2021 | 1751 | 0.10 | Why? |
| Thrombectomy | 1 | 2021 | 2272 | 0.10 | Why? |
| Thrombolytic Therapy | 1 | 2021 | 2218 | 0.09 | Why? |
| Animals | 8 | 2020 | 78931 | 0.09 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.09 | Why? |
| Young Adult | 9 | 2021 | 93724 | 0.09 | Why? |
| B-Lymphocytes | 2 | 2020 | 4418 | 0.09 | Why? |
| Pandemics | 17 | 2021 | 389249 | 0.09 | Why? |
| Disease Transmission, Infectious | 2 | 2020 | 9044 | 0.09 | Why? |
| Drug Delivery Systems | 1 | 2018 | 1365 | 0.09 | Why? |
| Syndrome | 1 | 2013 | 1310 | 0.09 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.09 | Why? |
| Staphylococcal Infections | 1 | 2017 | 1099 | 0.09 | Why? |
| Epitopes | 1 | 2020 | 4113 | 0.09 | Why? |
| Point-of-Care Testing | 1 | 2021 | 2782 | 0.09 | Why? |
| Mice, Inbred C57BL | 1 | 2018 | 5542 | 0.08 | Why? |
| Health Communication | 1 | 2018 | 1120 | 0.08 | Why? |
| Internationality | 1 | 2020 | 3297 | 0.08 | Why? |
| Patient Care Management | 1 | 2018 | 1514 | 0.08 | Why? |
| Child | 5 | 2021 | 70012 | 0.08 | Why? |
| Ceftriaxone | 2 | 2019 | 365 | 0.08 | Why? |
| Prenatal Care | 1 | 2017 | 1314 | 0.08 | Why? |
| Predictive Value of Tests | 2 | 2017 | 9537 | 0.08 | Why? |
| Gene Expression Regulation | 1 | 2019 | 4020 | 0.08 | Why? |
| Catheterization | 1 | 2008 | 264 | 0.08 | Why? |
| SARS Virus | 3 | 2004 | 13021 | 0.08 | Why? |
| Mutation, Missense | 1 | 2012 | 863 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Iatrogenic Disease | 1 | 2008 | 304 | 0.08 | Why? |
| Military Personnel | 2 | 2019 | 1097 | 0.08 | Why? |
| Viruses | 1 | 2019 | 2238 | 0.07 | Why? |
| Liver Diseases | 1 | 2021 | 2698 | 0.07 | Why? |
| Neutralization Tests | 1 | 2019 | 6698 | 0.07 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.07 | Why? |
| Schools | 1 | 2021 | 4187 | 0.07 | Why? |
| Delivery of Health Care | 3 | 2020 | 15909 | 0.07 | Why? |
| Brain Ischemia | 1 | 2020 | 2813 | 0.07 | Why? |
| Hematologic Neoplasms | 1 | 2018 | 2105 | 0.07 | Why? |
| Age Factors | 3 | 2021 | 21039 | 0.07 | Why? |
| Hemorrhage | 1 | 2017 | 3013 | 0.07 | Why? |
| C-Reactive Protein | 1 | 2021 | 7972 | 0.07 | Why? |
| Phylogeny | 3 | 2020 | 13341 | 0.07 | Why? |
| Aedes | 2 | 2018 | 380 | 0.07 | Why? |
| Pregnancy | 3 | 2021 | 23879 | 0.07 | Why? |
| Heart Diseases | 1 | 2021 | 3503 | 0.07 | Why? |
| Adenosine Monophosphate | 1 | 2021 | 5652 | 0.06 | Why? |
| Alanine | 1 | 2021 | 5687 | 0.06 | Why? |
| Survival Analysis | 3 | 2020 | 7592 | 0.06 | Why? |
| Thrombocytopenia | 1 | 2017 | 2093 | 0.06 | Why? |
| Aged | 14 | 2021 | 215776 | 0.06 | Why? |
| Mass Screening | 1 | 2003 | 8005 | 0.06 | Why? |
| Spike Glycoprotein, Coronavirus | 4 | 2021 | 37182 | 0.06 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.06 | Why? |
| Risk Factors | 7 | 2021 | 71621 | 0.06 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.06 | Why? |
| Limit of Detection | 2 | 2021 | 2698 | 0.06 | Why? |
| Treatment Outcome | 5 | 2021 | 51732 | 0.06 | Why? |
| Incidence | 5 | 2021 | 25622 | 0.06 | Why? |
| Malaysia | 2 | 2017 | 1116 | 0.06 | Why? |
| Vaccination | 4 | 2021 | 19050 | 0.06 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.06 | Why? |
| Antibodies, Neutralizing | 2 | 2019 | 25288 | 0.06 | Why? |
| Mice | 2 | 2018 | 21357 | 0.06 | Why? |
| Virus Diseases | 1 | 2019 | 3779 | 0.06 | Why? |
| Aged, 80 and over | 4 | 2020 | 88759 | 0.05 | Why? |
| Zika Virus | 3 | 2019 | 1924 | 0.05 | Why? |
| Peptides | 1 | 2013 | 2513 | 0.05 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 9706 | 0.05 | Why? |
| Brain-Derived Neurotrophic Factor | 1 | 2021 | 133 | 0.05 | Why? |
| Protective Clothing | 1 | 2004 | 468 | 0.05 | Why? |
| Hydroxychloroquine | 2 | 2021 | 12447 | 0.05 | Why? |
| Radiography, Thoracic | 1 | 2017 | 5486 | 0.05 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2020 | 6653 | 0.05 | Why? |
| Registries | 1 | 2020 | 12327 | 0.05 | Why? |
| Seroconversion | 2 | 2021 | 2515 | 0.05 | Why? |
| Immunoglobulin G | 2 | 2021 | 21571 | 0.05 | Why? |
| Leukocyte Count | 2 | 2021 | 3178 | 0.05 | Why? |
| Genotype | 1 | 2012 | 4697 | 0.05 | Why? |
| Patient Isolation | 2 | 2003 | 3182 | 0.05 | Why? |
| China | 3 | 2021 | 50654 | 0.05 | Why? |
| Disease Management | 1 | 2017 | 6841 | 0.05 | Why? |
| Biomarkers | 2 | 2020 | 23361 | 0.05 | Why? |
| Piperacillin | 1 | 2018 | 63 | 0.05 | Why? |
| Postoperative Complications | 1 | 2017 | 5861 | 0.05 | Why? |
| Staphylococcus aureus | 2 | 2017 | 844 | 0.05 | Why? |
| Comorbidity | 5 | 2021 | 34796 | 0.05 | Why? |
| Drug Resistance, Bacterial | 2 | 2018 | 1414 | 0.05 | Why? |
| Exercise | 1 | 2019 | 6771 | 0.05 | Why? |
| Premenopause | 1 | 2018 | 63 | 0.05 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.04 | Why? |
| Tumor Suppressor Proteins | 1 | 2019 | 165 | 0.04 | Why? |
| Borneo | 1 | 2017 | 14 | 0.04 | Why? |
| Immunologic Tests | 1 | 2021 | 445 | 0.04 | Why? |
| Trans-Activators | 1 | 2019 | 170 | 0.04 | Why? |
| Wound Infection | 1 | 2018 | 66 | 0.04 | Why? |
| Caffeine | 1 | 2018 | 67 | 0.04 | Why? |
| Program Development | 1 | 2004 | 1089 | 0.04 | Why? |
| Amoxicillin-Potassium Clavulanate Combination | 1 | 2017 | 72 | 0.04 | Why? |
| Pyelonephritis | 1 | 2018 | 66 | 0.04 | Why? |
| Coffee | 1 | 2018 | 79 | 0.04 | Why? |
| Microbial Sensitivity Tests | 2 | 2019 | 2886 | 0.04 | Why? |
| Australia | 2 | 2018 | 6306 | 0.04 | Why? |
| Accelerometry | 1 | 2019 | 228 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Stroke | 1 | 2020 | 8839 | 0.04 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.04 | Why? |
| Case-Control Studies | 3 | 2021 | 17671 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.04 | Why? |
| Insect Bites and Stings | 1 | 2017 | 63 | 0.04 | Why? |
| Equivalence Trials as Topic | 1 | 2017 | 242 | 0.04 | Why? |
| Microbiological Techniques | 1 | 2018 | 232 | 0.04 | Why? |
| Sus scrofa | 1 | 2017 | 205 | 0.04 | Why? |
| Program Evaluation | 1 | 2004 | 1929 | 0.04 | Why? |
| Hospitals, Teaching | 1 | 2004 | 1609 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Immunodominant Epitopes | 1 | 2020 | 813 | 0.04 | Why? |
| Mosquito Vectors | 1 | 2018 | 351 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| Insect Vectors | 1 | 2017 | 227 | 0.04 | Why? |
| Nanotechnology | 1 | 2021 | 821 | 0.04 | Why? |
| Liver Function Tests | 1 | 2021 | 1325 | 0.03 | Why? |
| Wettability | 1 | 2013 | 8 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| Photoelectron Spectroscopy | 1 | 2013 | 24 | 0.03 | Why? |
| Genome, Bacterial | 1 | 2018 | 446 | 0.03 | Why? |
| Immobilized Proteins | 1 | 2013 | 47 | 0.03 | Why? |
| Dimethylpolysiloxanes | 1 | 2013 | 46 | 0.03 | Why? |
| Carbapenems | 1 | 2017 | 343 | 0.03 | Why? |
| Conjunctivitis, Viral | 1 | 2018 | 301 | 0.03 | Why? |
| Demography | 1 | 2020 | 1660 | 0.03 | Why? |
| Models, Biological | 1 | 2011 | 4907 | 0.03 | Why? |
| Medical Staff, Hospital | 1 | 2004 | 1258 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Risk Assessment | 3 | 2020 | 25439 | 0.03 | Why? |
| Fatal Outcome | 1 | 2003 | 3438 | 0.03 | Why? |
| Policy Making | 1 | 2020 | 829 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2017 | 15421 | 0.03 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.03 | Why? |
| RNA, Viral | 3 | 2021 | 32276 | 0.03 | Why? |
| Cell Adhesion | 1 | 2013 | 230 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Observational Studies as Topic | 1 | 2020 | 1887 | 0.03 | Why? |
| Solubility | 1 | 2013 | 382 | 0.03 | Why? |
| Myocytes, Smooth Muscle | 1 | 2013 | 127 | 0.03 | Why? |
| Myalgia | 1 | 2018 | 1015 | 0.03 | Why? |
| Ferritins | 1 | 2021 | 2055 | 0.03 | Why? |
| Retrospective Studies | 4 | 2021 | 105322 | 0.03 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 1 | 2014 | 8843 | 0.03 | Why? |
| Semen | 1 | 2018 | 550 | 0.03 | Why? |
| Pseudomonas aeruginosa | 1 | 2017 | 652 | 0.03 | Why? |
| Flow Cytometry | 1 | 2021 | 2393 | 0.03 | Why? |
| Platelet Count | 1 | 2018 | 1381 | 0.03 | Why? |
| Health Care Costs | 1 | 2020 | 1007 | 0.03 | Why? |
| Metagenomics | 1 | 2018 | 823 | 0.03 | Why? |
| Emigrants and Immigrants | 1 | 2020 | 888 | 0.03 | Why? |
| World Health Organization | 1 | 2004 | 4213 | 0.03 | Why? |
| Nose | 1 | 2017 | 1093 | 0.03 | Why? |
| Endovascular Procedures | 1 | 2021 | 1302 | 0.03 | Why? |
| Adenosine Triphosphate | 1 | 2013 | 294 | 0.03 | Why? |
| Hong Kong | 1 | 2020 | 3361 | 0.03 | Why? |
| New Zealand | 1 | 2018 | 2073 | 0.03 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.03 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.03 | Why? |
| Endothelial Cells | 1 | 2021 | 2048 | 0.03 | Why? |
| Adolescent | 3 | 2020 | 86841 | 0.03 | Why? |
| Nursing Staff, Hospital | 1 | 2004 | 1554 | 0.03 | Why? |
| Convalescence | 1 | 2021 | 2829 | 0.02 | Why? |
| Phosphoproteins | 1 | 2020 | 4346 | 0.02 | Why? |
| Microbial Viability | 1 | 2013 | 406 | 0.02 | Why? |
| Workload | 1 | 2020 | 1887 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Candida | 1 | 2013 | 425 | 0.02 | Why? |
| Immune System | 1 | 2019 | 1479 | 0.02 | Why? |
| Cross Reactions | 1 | 2020 | 4374 | 0.02 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2021 | 3444 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.02 | Why? |
| Cells, Cultured | 1 | 2019 | 5835 | 0.02 | Why? |
| Academic Medical Centers | 1 | 2020 | 3088 | 0.02 | Why? |
| Antifungal Agents | 1 | 2018 | 1828 | 0.02 | Why? |
| Time Factors | 2 | 2021 | 31397 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.02 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.02 | Why? |
| Whole Genome Sequencing | 1 | 2018 | 3239 | 0.02 | Why? |
| Japan | 1 | 2020 | 6653 | 0.02 | Why? |
| Monocytes | 1 | 2019 | 2978 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Hypoxia | 1 | 2021 | 3626 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.02 | Why? |
| Cohort Studies | 2 | 2020 | 36005 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Acute Disease | 1 | 2018 | 6029 | 0.02 | Why? |
| Communicable Diseases | 1 | 2020 | 2148 | 0.02 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.02 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.02 | Why? |
| Antibody Formation | 1 | 2018 | 4038 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| General Surgery | 1 | 2017 | 1472 | 0.02 | Why? |
| Tuberculosis | 1 | 2020 | 2895 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2021 | 9091 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Specimen Handling | 1 | 2021 | 6190 | 0.02 | Why? |
| Mortality | 1 | 2020 | 7132 | 0.02 | Why? |
| Contact Tracing | 1 | 2003 | 8448 | 0.02 | Why? |
| Lung | 2 | 2020 | 31049 | 0.02 | Why? |
| Signal Transduction | 1 | 2019 | 7207 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Inpatients | 1 | 2017 | 5161 | 0.01 | Why? |
| United Kingdom | 1 | 2020 | 18046 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2018 | 10998 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Multivariate Analysis | 1 | 2011 | 5440 | 0.01 | Why? |
| Tertiary Care Centers | 1 | 2017 | 8248 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2017 | 5164 | 0.01 | Why? |
| Brazil | 1 | 2017 | 12582 | 0.01 | Why? |
| Peptidyl-Dipeptidase A | 1 | 2020 | 9659 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Genome, Viral | 1 | 2020 | 13157 | 0.01 | Why? |
| Infant | 1 | 2020 | 30274 | 0.01 | Why? |
| Hospitals | 1 | 2017 | 11793 | 0.01 | Why? |
| Quarantine | 1 | 2004 | 18418 | 0.01 | Why? |
| Coronavirus | 1 | 2004 | 18339 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2011 | 11304 | 0.01 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 13720 | 0.01 | Why? |